Here’s how small-cap biotech Dynavax Technologies Corporation (NASDAQ:DVAX) would like its story to play out: Hepatitis B vaccine Heplisav-B wins FDA approval in December. The company begins marketing the vaccine in 2017. Heplisav-B then goes on to quickly exceed sales projections. Dynavax’s stock soars.
That’s plan A. But does Dynavax need a plan B? And if so, what is it?
